Entero Therapeutics Appoints New CEO, Dr. David J. Mazzo
Ticker: GRDX · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, ceo-appointment
TL;DR
Entero Therapeutics has a new CEO, Dr. David J. Mazzo, replacing Dr. James R. Bianco.
AI Summary
Entero Therapeutics, Inc. announced on August 16, 2024, the appointment of Dr. David J. Mazzo as Chief Executive Officer and a member of the Board of Directors. Dr. Mazzo, who previously served as Chief Scientific Officer, will lead the company's strategic direction and operational execution. The company also reported the departure of former CEO, Dr. James R. Bianco, effective August 16, 2024.
Why It Matters
A change in CEO can signal a shift in company strategy or operational focus, potentially impacting future performance and investor outlook.
Risk Assessment
Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and execution, impacting the company's stability and performance.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- Dr. David J. Mazzo (person) — Appointed Chief Executive Officer and Board Member
- Dr. James R. Bianco (person) — Departing Chief Executive Officer
- August 16, 2024 (date) — Effective date of CEO change
FAQ
Who has been appointed as the new CEO of Entero Therapeutics, Inc.?
Dr. David J. Mazzo has been appointed as the new Chief Executive Officer of Entero Therapeutics, Inc.
When was the appointment of the new CEO effective?
The appointment of Dr. David J. Mazzo as CEO was effective August 16, 2024.
Who was the previous CEO of Entero Therapeutics, Inc.?
Dr. James R. Bianco was the former Chief Executive Officer of Entero Therapeutics, Inc.
What other role has Dr. David J. Mazzo taken on at Entero Therapeutics, Inc.?
In addition to CEO, Dr. David J. Mazzo has also been appointed as a member of the Board of Directors.
What was Dr. Mazzo's previous role within Entero Therapeutics, Inc.?
Prior to his appointment as CEO, Dr. David J. Mazzo served as the Chief Scientific Officer of Entero Therapeutics, Inc.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-08-22 17:28:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
Filing Documents
- tm2422450d1_8k.htm (8-K) — 25KB
- 0001104659-24-092061.txt ( ) — 194KB
- fwbi-20240816.xsd (EX-101.SCH) — 3KB
- fwbi-20240816_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240816_pre.xml (EX-101.PRE) — 22KB
- tm2422450d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' Compensatory Arrangements of Certain Officers. Board Resignation On August 16, 2024, Chaitan Khosla resigned as a member of the Board of Directors (the "Board") of Entero Therapeutics, Inc. (the "Company"), effective immediately. On August 21, 2024, the Board appointed Mr. Timothy Ramdeen to serve as a member of the Audit Committee of the Board, filling the vacancy created by Dr. Khosla's resignation. Chief Executive Officer Compensation On August 19, 2024, the independent directors of the Board approved the payment of the post-employment medical insurance premiums for James Sapirstein, CEO, for six months while Mr. Sapirstein is serving as Chief Executive Officer. Such premiums are being paid to maintain existing levels of coverage to which Mr. Sapirstein was entitled prior to the termination of his employment agreement on August 2, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. August 22, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer